Zusammenfassung
Molekularbiologische Methoden, einschließlich der Gentherapie, sind in den letzten Jahren zunehmend ins Rampenlicht gerückt. Nach experimentellen Erfolgen und einer dementsprechend hohen Erwartungshaltung insbesondere bei der Therapie von Patienten mit hohem Leidensdruck, bei denen konventionelle Therapien bisher versagten, erfolgte bereits nach wenigen Jahren der Übergang in die klinische Testung. Nach der 1. therapeutischen Anwendung 1990 hat sich das große Potential der Gentherapie bestßtigt, wenn auch der Weg zur routinemßßigen Anwendung lßnger als erwartet ist.
Chapter PDF
Similar content being viewed by others
Literatur
Aebischer P., Schluep M., Deglon N. et al. (1996) Erratum: Intrathecal delivery of CNTF using encapsulated genetieally modified xenogeneic cells in amyotrophie lateral sderosis patients. (Nat Med (1996) 2:696-699). Nat Med 2:1041
Albelda S.M. (1997) Gene therapy for lung cancer and mesothelioma. Chest [Suppl6] 111):144S–149S
Anderson R.J., Galatowiez G., Macdonald I.D., Lowdell M.W., Corbett T.J., Prentice H.G. (1997) Detection of adeno associated virus type 2 in sorted human bone marrow progenitor cells. Exp Hematol 25:256–262
Barinaga M. (1993) Ribozymes: killing the messenger. Science 262:1512–1514
Barnes M.N., Deshane J.S., Rosenfeld M., Siegal B.G., Curiel D.T., Alvarez R.D. (1997) Gene therapy and ovarian cancer: a review. Obstet Gynecol 89:145–155
Bauer K.A. (1994) Hypercoagulability-A new cofactor in the protein C antieoagulant pathway. N Engl J Med 330:566–567
Baumgartner I., Pieczek A., Manor O. et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114–1123
Belli F., Arienti F., Sulesuso J. et al. (1997) Active immunization of metastatic melanoma patients with interleukin 2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197–203
Bellon G., Michelcalemard L., Thouvenot D. et al. (1997) Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 8:15–25
Blaese R.M., Anderson W.F., Culver K.W., Rosenberg S.A. (1990) The ADA human gene therapy dinieal protocol. Hum Gene Ther 1:327–362
Blaese R.M., Culver K.W., Miller A.D. et al. (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475–480
Bonini C., Ferrari G., Verzeletti S. et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719–1724
Bordignon C., Bonini C., Verzeletti S. et al. (1995a) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneie bone marrow transplantation. Hum Gene Ther 6:813–819
Bordignon C., Notarangelo L.D., Nobili N. et al. (1995b) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470–475
Boucher R.C., Knowles M.R., Johnson L.G. et al. (1994) Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel HilI. Hum Gene Ther 5:615–639
Buchschacher G.J., Panganiban A.T. (1992) Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 66:2731–2739
Bukrinsky M.I., Haggerty S., Dempsey M.P. et al. (1993) A nudear localization signal within HI-1 matrix protein that governs infection of non-dividing cells. Nature 365:666–669
Bums J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90:8033–8037
Burrows F.J., Thorpe P.E. (1994) Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol Ther 64:155–174
Burt K., Chema D., Timmons T. (1997) Tracing the dissemination of adenoviral vectors in patient body fluids (abstract). J Mol Med [Suppl 5] 75:B28(86)
Calarota S., Bratt G., Nordlund S. et al. (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320–1325
Caplen N.J., Alton E.W., Middleton P.G. et al (1995) Liposomemediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1:39–46
Chan P.J., Kalugdan T., Su B.C. et al. (1995) Sperm as a noninvasive gene delivery system for preimplantation embryos. Fertil Steril 63: 1121–1124
Chang M.W., Barr E., Min-Min-Lu, Barton K., Leiden J.M. (1995a) Adenovirus-mediated over-expression of the cyclin/cydin-dependent kinase inhibitor, p21 inhibits smooth musde cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 96:2260–2268
Chang M.W., Barr E., Seltzer J. et al. (1995b) Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of retinoblastoma gene product. Science 267:518–522
Chonn A., Cullis P.R. (1995) Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 6:698–708
Conry R.M., LoBuglio A.F., Curiel D.T. (1996) Polynudeotidemediated immunization therapy of cancer. Semin Oncol 23:135–147
Cornetta K., Srour E.F., Moore A. et al. (1996) Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum Gene Ther 7:1323–1329
Crystal R.G. (1995) Transfer of genes to humans: early lessons and obstades to success. Science 270:404–410
Crystal R.G., McElvaney N.G., Rosenfeld M.A. et al. (1994) Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8:42–51
Crystal R.G., Jaffe A., Brody S. et al. (1995) A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis trans membrane conductance regulator gene in the lung. Hum Gene Ther 6:643–666
Culver K.W., Blaese R.M. (1994) Gene therapy for cancer. Trends Genet 10:174–178
Culver K.W., Osborne W.R., Miller A.D. et al. (1991 a) Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc 23: 170–171
Culver K.W., Anderson W.F., Blaese R.M. (1991 b) Lymphocyte gene therapy. Hum Gene Ther 2:107–109
Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584
Davidson A., Morey S., Musk A.W. et al. (1997) Gene therapy or therapy by intratumoral cytokines by infusion in mesothelioma patients. Lung Cancer [Suppl 2] 18:94
Deisseroth A.B., Kavanagh J., Charnplin R. (1994) Clinical protocol: use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 5:1507–1522
Deshane J., Siegal G.P., Wang M.H. et al. (1997) Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti Erbb 2 intracellular single chain antibody for ovarian cancer gene therapy. Gynecol Oncol 64:378–385
Diehek D.A., Neville R.F., Zwiebel J.A., Freeman S.M., Leon M.B., Anderson W.F. (1989) Seeding of intravascular stents with genetieally engineered endothelial cells. Circulation 80:1347–1353
Docherty K. (1997) Gene therapy for diabetes mellitus. Clin Sci 92:321–330
Dube I.D., Cournoyer D., (1995) Gene therapy: here to stay. Can Med Assoc J 152:1605–1613
Dunbar C., Kohn D., Karlsson S. et al. (1996) Retroviral mediated transfer of the cDNA for human glucocerebro-sidase into hematopoietie stern cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 7:231–253
During M. (1996a) Gene therapy chronology. Science 273:416–417
During M.J. (1996b) Gene trial in New Zealand. Lancet 348:618
Ekhterae D., Stanley J.C. (1995) Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. J Vasc Surg 21:953–962
Engel B.C., Laws H.J., Buttlies B., Kahn T., Gobel U., Burdach S.E.G. (1998) Induction of a CD3+/CD56+ lymphocyte population following gene therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroecto-dermal malignancy. Med Pediatr Oncol 31:56–60
Essex M., Matsuda Z., Yu X., Lee T.H. (1995) Gene therapy against retroviral diseases. Leukemia 9:71–74
European Working Group of Gene Therapy E (1996) Newsletter No. i5
Evans C.H., Mankin H.J., Ferguson A.B. Jr et al. (1996) Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritie cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7:1261–1306
Feldman L.J., Isner J.M. (1995) Gene therapy for the vulnerable plaque. J Am Coll Cardiol 26:826–835
Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L. (1995) A phase I trial of B7-transfected or parentallethally irradiated allogeneie melanoma cell lines to induce cellmediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 6:87–106
Flotte T.R., Afione S.A., Zeitlin P.L. (1994) Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11:517–521
Flotte T.R., Conrad C., Reynolds T.Z. (1995) Preclinical evaluation of AAV vectors expressing the human CFTR cDNA (abstract). J Cell Biochem [Suppl 21A] 364:C366–112
Flotte T.R., Carter B., Conrad C. et al. (1996) A phase 1 study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gen Ther 7:1145–1159
Flügel R.M. (1991) Spumaviruses: a group of complex retroviruses. J Acquir Immune Defic Syndr Hum Retrovirol 4:739–750
Freeman T.B. (1997) From transplants to gene therapy for Parkinsons disease. Exp Neurol 144:47–50
Freeman S.M., McCune M.C., Robinson E. (1992) Treatment of ovarian cancer using HSV-TK gene-modified vaccine. Hum Gene Ther 3:342
Freese A., Stern M., Kaplitt M.G. et al. (1996) Prospects for gene therapy in Parkinsons disease. Mov Disord 11:469–488
Friedmann T. (1996) Human gene therapy-an immature genie, but certainly out of the bottle. Nat Med 2:144–147
Fujiwara T., Grimm E.A., Roth J.A. (1994) Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 6:96–105
Gahery-Segard H., Molinier-Frenkel V., Le Boulaire C. et al. (1997) Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 100:2218–2226
Galpin J.E., Casciato D.A., Richards S.B. (1994) A phase I clinical trial to evaluate the safety and biologieal activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatie HIV-1 infected subjects. Hum Gene Ther 5:997–1017
Gßnsbacher B., Notzer R., Houghton A. et al. (1992) A pilot study of immunization with interleukin-2 secreting allogenic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther 3:691–703
Gßnsbacher B., Rosenthai F.M., Zier K. (1993) Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 11:345–354
Gill D.R., Southern K.W., Mofford K.A. et al. (1997) A placebo controlled study of liposome mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4:199–209
Ginsberg H.S. (ed) (1984) The adenoviruses. Plenum Press, New York
Greene W.C. (1991) The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 324:308–317
Grossman M., Raper S.E., Kozarsky K. et al. (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6:335–341
Grossman M., Rader D.J., Muller D.W. et al. (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1:1148–1154
Günzburg W.H., Salmons B. (1992) Factors controlling the expression of mouse mammary tumour virus. Biochem J 283:625–632
Günzburg W.H., Salmons B. (1995) Virus vector design in gene therapy. Mol Med Today 1:410–417
Habib N.A., Ding S.F., El-Masry R. et al. (1996) Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 20:103–107
Halbert C.L., Alexander I.E., Wolgamot G.M., Miller H.D. (1995) Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. Virology 69:1473–1479
Halpern M.D., Pisetsky D.S. (1995) In vitro inhibition of murine IFN gamma production by phosporothioate deoxyguanosine oligomers. Immunopharmacology 29:47–52
Harris J.D., Lemoine N.R. (1996) Strategies for targeted gene therapy. Trends Genet 12:400–405 Harrison’s principles of internal medicine, 13th edn (1994) McGraw-Hill, New York
Hatzoglou M., Lamers W., Bosch F., Wynshaw B.A., Clapp D.W., Hanson R.W. (1990) Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J Biol Chem 265:17285–17293
Haubrich R., McCutchan J.A., Holdredge R., Heiner L., Merritt J., Merchant B. (1995) An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-1-IT (V) (HIV-1(IIIB)(env/rev) retroviral vector) in HIV-1-infected subjects. Hum Gene Ther 6:941–955
Hay J.G., McElvaney N.G., Herena J., Crystal R.G. (1995) Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of anormal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 6: 1487–1496
Herrman J.P.R., Hermans W.R., Vos J., Serruys P.W. (1993) Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Gram (Part I). Drugs 46:18–52
Herweijer H., Latendresse J.S., Williams P. et al. (1995) A plasmid-based self-amplifying sindbis virus vector. Hum Gene Ther 6:1161–1167
Hesdorffer C., Antman K., Bank A., Fetell M., Mears G., Begg M. (1994) Clinical protocol: human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 5:1151–1160
Hesdorffer C., Ayello J., Ward M. et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing highdose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 16: 165–172
Hijiya N., Zhang J., Ratajczak M.Z. et al. (1994) Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci USA 91:4499–4503
Hoogerbrugge P.M., von Beusechem V.W., Kaptein L.C., Einerhand M.P., Valerio D. (1995) Gene therapy for adenosine deaminase deficiency. Br Med Bull 51:72–81
Hoogerbrugge P.M., Van Beusechem V.W., Fischer A. et al. (1996) Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3: 179–183
Horowitz M.S. (1990) Adenoviridaee and their replication. In: Fields B.N., Knipe D.M. (eds) Virology. Raven Press, New York, pp 1679–1740
Hsieh S.Y., Taylor J. (1992) Delta virus as a vector for the delivery of biologically-aetive RNAs: possibly a ribozyme speeifie for chronic hepatitis B virus infection. Adv Exp Med Biol 312:125–128
Huebner R.J., Rowe W.P., Ward T.G. et al. (1954) Adenoidal-pharyngeal-conjunctival agents. N Engl J Med 251:1077–1086
Huehns T.Y., Krausz E., Mrochen S. et al. (1999) Neointimal growth ean be influenced by local adventitial gene manipulation via a needle injeetion catheter. Atherosclerosis 144:135–150
Hui K.M., Ang P.T., Huang L., Tay S.K. (1997) Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 4:783–790
Isner J.M. (1998) Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. Adv Drug Deliv Rev 30:185–197
Isner J.M., Walsh K., Symes J. et al. (1995) Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Cireulation 91:2687–2692
Isner J.M., Pieczek A., Schainfeld R. et al. (I996a) Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF165 in patients with isehaemic limb. Lancet 348:370–374
Isner J.M., Walsh K., Symes J. et al. (1996b) Clinical protocol: arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 7:959–988
Isner J.M., Walsh K., Rosenfield K. et al. (1996e) Arterial gene therapy for restenosis. Hum Gene Ther 7:989–1011
Izquierdo M., Cortes M.L., Martin V. et al. (1997) Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir Suppl (Wien) 68:111–117
Jantscheff P., Bongartz G., Dietrich P.Y. et al. (1997) Phase I study of cytokine-transfected xenogeneic cells (Vero-IL2) in patients with metastatic solid tumors. J Mol Med 75:B31
Juengst E.T. (1995) Prevention and the goals of genetic medicine. Hum Gene Ther 6:1595–1605
Kalle C. von, Kiem H.P., Goehle S. et al. (1994) Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84:2890–2897
Kircheis R., Kichler A., Wallner G. et al. (1997) Coupling of cell binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 4:409–418
Knowles M.R., Hohneker K.W., Zhou Z. et al. (1995) A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823–831
Kohn D., Weinberg K.I., Parkman P. et al. (1993) Gene therapy for neonates with ADA-deficient SCID by retroviralmediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. Blood [Suppl 1] 82:315a
Kohn D.B., Weinberg K.I., Nolta J.A. et al. (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1:1017–1023
Kohn D.B., Hershfield M.S., Corbonaro D. et al. (1998) T lymphocytes with anormal ADA gene accumulate after transplantation of transduced autologous umbilieal cord blood CD34+ cells in ADA-defieient SCID neonates. Nat Med 4:775–780
Kutryk M.J.B., Groot M.R. de, Brand M. van den et al. (1997) Feasibility of the local delivery of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: acute results of the Thoraxeentre „ITALICS” trial. 14th Congress of the European Society of Cardiology, Stockholm, p 2918
Laitinen M., Pakkanen T., Donetti E. et al. (1997) Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 8:1645–1650
Lang Z.H., Feingold J.M. (1996) An autonomously replicating eukaryotic expression vector with a tetracycline responsive promoter. Gene 168:169–171
Ledley F.D. (1995) Nonviral gene therapy: the promise of genes as pharmaceutieal products. Hum Gene Ther 6:1129–1144
Lee S.W., Kahn M.L., Dichek D.A. (1992) Expression of an anchored urokinase in the apieal endothelial cell membrane. Preservation of enzymatie activity and enhancement of cell surface plasminogen activation. J Biol Chem 267:13020–13027
Lee S.W., Kahn M.L., Dichek D.A. (1993) Control of clot lysis by gene transfer. Trends Cardiovasc Med 3:61–66
Lewis P.F., Emerman M. (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510–516
Link C.J., Moorman D., Seregina T., Levy J.P., Schabold K.J. (1995) A phase I trial of in vivo gene therapy with the Herpes simplex thymidine kinase ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Cancer Gene Ther 2:230–231
Liu J.M. (1998) Gene transfer for the eventual treatment of Fanconi’s anemia. Semin Hematol 35: 168–179
Liu J.M., Young N.S., Walsh C.E. et al. (1997) Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietie progenitors of group C patients. Hum Gene Ther 8:1715–1730
Losordo D.W., Vale P.R., Symes I.F. et al. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800–2804
Lotze M.T., Rubin I.T. (1995) Report of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH)
Lotze M.T., Rubin J.T., Carty S. et al. (1994) Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5:41–55
Lu D.R., Zhou J.M., Zheng B. et al. (1993) Stage I clinical trial of gene therapy for hemophilia B. Sci China B 36:1342–1351
MacGregor R.R., Boyer J.D., Ugen K.E. et al. (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92–100
Mackensen A., Veelken H., Lahn M. et al. (1997) Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 75:290–296
Malech H.L., Maples P.B., Whiting-Theobald N. et al. (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94:12133–12138
Malkin D., Portwine C. (1994) The geneties of childhood cancer. Eur J Cancer 30a:1942–1946
Marcel T., Grausz J.D. (1996) TCM Worldwide Gene Therapy Enrollment Report. TMC Development
Marshali E. (1996) New Zealand’s leap into gene therapy. Science 271: 1489–1490
Matrangeli A., Harvey B.G., Yao J. (1994) Effieient in vivo adenovirus-mediated gene transfer to the airway epithelium of animals immunized with differnt adenovirus serotypes. North Ameriean Cystic Fibrosis Meeting. Late Breaking Sciene S5–6
McElvaney N.G., Crystal R.G. (1995) IL-6 release and airway administration of human CFTR cDNA adenovirus vector [2]. Nat Med 1:182–184
Mebatsion T., Schnell M.J., Cox I.H., Finke S., Conzelmann K.K. (1996) Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci USA 93:7310–7314
Merrouche Y., Negrier S., Bain C. et al. (1995) Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 13:410–418
Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrieh A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579
Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938–943
Motulski A., Orkin S.C. (1995) Report and recommendation of the panel to assess the NIH investment in research on gene therapy. Website: http://www.nih.gov/news/panelrep.html
Mukherjee S., Haenel T., Epton M. (1997) Intralesional vaccinia virus-interleukin-2 (VV-IL-2) gene therapy in malignant mesothelioma (MM). Lung Cancer [Suppl 1] 18:236
Nabel E.G., Gordon D., Yang Z.Y. et al. (1992a) Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 3:649–656
Nabel G.J., Chang A., Nabel E.G. et al. (1992b) Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3:399–410
Nabel G.I., Nabel E.G., Yang Z.Y. et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologie activity, and lack of toxieity in humans. Proc Natl Acad Sci USA 90:11307–11311
Nabel E.G., Yang Z., Muller D. et al. (1994a) Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanorna. Hum Gene Ther 5:1089–1094
Nabel G.J., Chang A.E., Nabel E.G. et al. (1994b) Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 5:57–77
Nabel G.I., Yang Z.Y., Nabel E.G. et al. (1995) Direct gene transfer for treatment of human cancer. Ann N Y Acad Sci 772:227–231
Niemann T.H., Trigg M.E., Winick N., Penick G.D. (1993) Disseminated adenoviral infection presenting as acute pancreatitis. Hum Pathol 24:1145–1148
Nikol S., Huehns T.Y., Krausz E. et al. (1999) Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther 6:737–748
Noguiez Heilin P., Meur M.R., Salzmann J.L., Klatzmann D. (1996) Plasmoviruses: nonviral/viral vectors for gene therapy. Proc Natl Acad Sci USA 93:4175–4180
Oldfield E.H., Ram Z., Chiang Y., Blaese R.M. (1995) Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum Gene Ther 6:55–85
Onodera M., Ariga T., Kawamura N. et al. (1998) Successful peripheral T-Iymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91:30–36
O’Shaughnessy J.A., Cowan K.H., Nienhuis A.W. et al. (1994) Clinical protocol: retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stern cells during autologous transplantation after intensive chemotherapy for metastatie breast cancer. Hum Gen Ther 5:891–911
Parmiani G., Arienti F., Sulesuso J. et al. (1996) Tissue Culture Society Congress, Brno, April 21-24, 1996. Cytokine based gene therapy of human tumors. An overview. Folia Biol (Prah a) 42:305–309
Podsakoff G., Wong Jr K.K., Chatterjee S. (1994) Effieient gene transfer into nondividing ceils by adeno-assoeiated virusbased vectores. J Virol 68:5656–5666
Porteous D.J., Dorin J.R., McLachlan G. et al. (1997) Evidence for safety and efficacy of DOTAP cationie liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystie fibrosis. Gene Ther 4:210–218
Qiu X., Lu D., Zhou J. et a1. (1996) Implantation of autologous skin fibroblast genetieally modified to secrete clotting factor IX partially corrects the hemorrhagie tendeneies in two hemophilia B patients. Chin Med J (Engl) 109:832–839
Rakhmilevich A.L., Turner J., Ford M.J. et al. (1996) Gene gun mediated skin transfeetion with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291–6296
Ram Z., Culver K., Oshiro E. (1995) Summary of results and conclusions of the gene therapy of malignant brain tumors: Clinical study. J Neurosurg 82:343A
Recombinant DNA Advisory Committee (RAC) der NIH (1995) Data management seientific report and status report, Stand 2.6.1995
Recombinant DNA Advisory Committee (RAC) der NIH (1996) Human gene transfer protocols, Stand 26.4.1996
Redmond D.E. (1997) Gene therapy approaches to Parkinsons disease: preClinical to clinical trials, or what steps to take to get there from here. Exp Neurol 144:160–167
Riddell S.R., Elliott M., Lewinsohn D.A. et al. (1996) T-cell mediated rejection of gene-modified HlV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216–223
Rigg R.J., Chen J., Dando J.S., Forestell S.P., Plavec I., Bohnlein E. (1996) A novel human amphotropie packaging ceil line: high titer, complement resistance, and improved safety. Virology 218:290–295
Rosenberg S.A. (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199
Rosenberg Z.F., Fauei A.S. (1990) Immunopathogenic mechanisms of HlV infection: cytokine induction of HlV expression. Immunol Today 11:176
Rosenberg S.A., Aebersold P., Cornetta K. et a1. (1990) Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578
Rosenberg S.A., Yannelli J.R., Yang J.C. et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159–1166
Rossi J.J. (1995) Therapeutic antisense and ribozymes. Br Med Bull 51:217–225
Roth J.A. (1996) Modification of tumor suppressor gene expression in non small ceillung cancer (Nsclc) with a retroviral vector expressing wildtype (normal) p53. Hum Gene Ther 7:861–874
Roth J.A., Nguyen D., Lawrence D.D. et al. (1996) Retrovirus mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985–991
Roth J.A. (1997) 33rd American Soeiety of Clinical Oncology (ASCO) Annual Meeting (Abstract)
Roth J.A., Cristiano R.J. (1997) Gene therapy for cancer: what have we done and where are we going. J Natl Cancer Inst 89:21–39
Rubin J., Charboneau J.W., Reading C., Kovach J.S. (1994) Phase I study of immunotherapy of hepatie metastases of colorectal careinoma by direct gene transfer. Hum Gene Ther 5:1385–1399
Sakiyama Y. (1996a) Clinical study of gene therapy for ADA deficiency. Aerugi 45:621–626
Sakiyama Y. (1996 b) Gene therapy for adenosine deaminase deficiency. Hokkaido Igaku Zasshi 71:27–32
Samulski R.J. (1993) Adeno-assoeiated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 3:74–80
Scanlon K.J., Ohta Y., Ishida H. et a1. (1995) Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288–1296
Schadendorf D., Czarnetzki B.M., Wittig B. (1995) Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatie melanoma. J Mol Med 73:473–477
Schweigerer L. (1995) Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73:497–508
Sekhon H.S., Larson J.E. (1995) In utero gene transfer into the pulmonary epithelium. Nat Med 1:1201–1203
Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359:67–70
Sobol R.E., Fakhrai H., Shawler D. et a1. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164–167
Son K., Huang L. (1994) Exposure of human ovarian careinoma to eisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci USA 91:12669–12672
Spiegel M., Bitzer M., Schenk A. et al. (1998) Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F. J Virol 72:5296–5302
Stein C.A., Cheng Y.C. (1993) Antisense oligonucleotides as therapeutic agents-is the bullet really magieal? Science 261:1004–1012
Sterman D.H., Treat J., Litzky L.A. et al. (1998a) Adenovirusmediated herpes simplex virus thymidine kinase/ganeiclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9: 1083–1092
Sterman D.H., Kaiser L.R., Albelda S.M. (1998b) Gene therapy for malignant pleural mesothelioma. Gene Ther 12:553–568
Stopeck A.T., Hersh E.M., Akporiaye E.T. et al. (1997) Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341–349
Sun Y., Jurgovsky K., Moller P. et al. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481–490
Tait D.L., Obermiller P.S., Redlin-Frazier S. et al. (1997) A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3:1959–1968
Tan Y., Xu M., Wang W. et al. (1996) IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 16:1993–1998
Tjuvajev J.G., Stockhammer G., Desai R. et al. (1995) Imaging the expression of transfected genes in vivo. Cancer Res 55:6126–6132
Tolstoshev P. (1993) Gene therapy, concepts, current trials and future directions. Annu Rev Pharmacol Toxicol 33:573–596
Touchette N. (1996) Gene therapy-not ready for prime time. Nat Med 2:7–8
Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replicationdefective adenovirus vectors. Nat Med 2:545–550
Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., Schlom J. (1995) Generation of human cytotoxic T-cell specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine. J Natl Cancer lust 87:982–990
Tursz T., Cesne A.L., Baldeyrou P. et al. (1996) Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer lust 88:1857–1863
Ueba T., Nosaka T., Takahashi J.A. et al. (1994) Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and heptacellular carcinoma cells. Proc Natl Acad Sci USA 91:9009–9013
Van Meir E.G., Polverini P.J., Chanzin V.R., Huang H-J., Tribolet N. de, Cavenee W.K. (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8: 171–176
Veelken H., Mackensen A., Lahn M. et al. (1997) A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269–277
Waddill W., Wright W., Unger E., et al. (1997) Human gene therapy for melanoma: Ct guided interstitial injection. AJR Am J Roentgenol 169:63–67
Wagner E., Zenke M., Cotten M., Beug H., Birnstiel M.L. (1990) Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 87:3410–3414
Walker R., Bechtel C.M., Natarajan V. et al. (1995) Adoptive transfer of genetically modified, HIV-specific, syngeneic cytotoxic T lymphocytes (CTL) in HIV discordant identical twins. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, Abstract 404
Weber F., Bojar H., Priesack H.B. et al. (1997) Gene therapy of glioblastoma-one year clinical experience with ten patients (abstract). J Mol Med [Suppl 5] 75:B40
Welsh M.J., Zabner J., Graham S.M., Smith A.E., Moscicki R.
Wadsworth S. (1995) Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum Gene Ther 6:205–218
Wiley Stand 1.12.1998, Wiedergabe mit Erlaubnis von Wiley J. Gene Medicine. Website: http://www.wiley.co.uk/genmed.
Wills K.N., Maneval D.C., Menzel P. et al. (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079–1088
Wilson J.M. (1995) Report of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH)
Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. (1996) Expression of a protective gene prolongs survival of T cells in human immunodefieiency virus-infected patients. Proc Natl Acad Sci USA 93:2889–2894
Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. (1994a) Cellular immunity to viral antigens limits E 1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–4411
Yang Y., Nunes F.A., Berencsi K., Gonczol E., Engelhardt J.F., Wilson J.M. (1994 b) Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362–369
Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. (1996) Expression of a protective gene prolongs survival of T cells in human immunodefieiency virus-infected patients. Proc Natl Acad Sci USA 93:2889–2894
Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. (1994a) Cellular immunity to viral antigens limits E 1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–4411
Yang Y., Nunes F.A., Berencsi K., Gonczol E., Engelhardt J.F., Wilson J.M. (1994 b) Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362–369
Zabner J., Couture L.A., Gregory R.J., Graham S.M., Smith A.E., Welsh M.J. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207–216
Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. (1995) Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270:18997–19007
Zabner J., Ramsey B.W., Meeker D.P. et al. (1996) Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin luvest 97:1504–1511
Ziegner U.H., Peters G., Jolly D.J. et al. (1995) Cytotoxic T-Iymphocyte induction in asymptomatic HIV-1-infected patients immunized with retrovector-transduced autologous fibroblasts expressing HIV-HIIB Env/Rev proteins. AIDS 9:43–50
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Nikol, S. (2000). Aktueller Stand der Gentherapie. In: Ganten, D., Ruckpaul, K. (eds) Monogen bedingte Erbkrankheiten 2. Handbuch der Molekularen Medizin, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57044-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-57044-5_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62996-9
Online ISBN: 978-3-642-57044-5
eBook Packages: Springer Book Archive